...

首页> 外文期刊>Intelligence: A Multidisciplinary Journal >Real world data on treatment patterns before and after reporting of the KATHERINE trial: A phase 3 study of adjuvant Ado-trastuzumab emtansine (TDM1) versus trastuzumab in early stage HER plus breast cancer

【24h】

Real world data on treatment patterns before and after reporting of the KATHERINE trial: A phase 3 study of adjuvant Ado-trastuzumab emtansine (TDM1) versus trastuzumab in early stage HER plus breast cancer

机译：报告凯瑟琳试验前后治疗模式的现实数据：在早期患有乳腺癌的阶段佐剂ADO-Trastuzumab Emtansine（TDM1）的3阶段研究

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Intelligence: A Multidisciplinary Journal 》 |2020年第2020期| 共2页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类心理学 ;
关键词

相似文献

外文文献
中文文献
专利

1. Real world data on treatment patterns before and after reporting of the KATHERINE trial: A phase 3 study of adjuvant Ado-trastuzumab emtansine (TDM1) versus trastuzumab in early stage HER plus breast cancer [J] . Intelligence: A Multidisciplinary Journal . 2020 ,第期

机译：报告凯瑟琳试验前后治疗模式的现实数据：在早期患有乳腺癌的阶段佐剂ADO-Trastuzumab Emtansine（TDM1）的3阶段研究
2. The Quality of Reporting Harms-Related Data in Clinical Trials of Adjuvant Trastuzumab in Early-Stage Breast Cancer Treatment [J] . Ali Mahinbakht, Sayeh M. Lavasani, Micheal Guirguis Drug information journal . 2014 ,第3期

机译：曲妥珠单抗在早期乳腺癌治疗中的临床试验中报告危害相关数据的质量
3. The Quality of Reporting Harms-Related Data in Clinical Trials of Adjuvant Trastuzumab in Early-Stage Breast Cancer Treatment [J] . Mahinbakht Ali, Lavasani Sayeh M., Guirguis Micheal Therapeutic innovation & regulatory science. . 2014 ,第3期

机译：曲妥珠单抗在早期乳腺癌治疗中的临床试验中报告危害相关数据的质量
4. Elevated WBP2 Expression in HER2-Positive Breast Cancers Correlates with Sensitivity to Trastuzumab-Based Neo-Adjuvant Therapy: A Retrospective and Multicentric Study [C] . Yoon Pin Lim International Molecular Medicine Tri-Conference. . 2019

机译：HER2阳性乳腺癌中的WBP2表达升高与基于曲妥珠单抗的新辅助治疗的敏感性相关：回顾性和多中心研究
5. A phase Ib study of safety and pharmacokinetics of trastuzumab emtansine and pertuzumab in Japanese patients with HER2-positive metastatic breast cancer [D] . NOGUCHI, Emi 2019

机译：Ib期研究曲妥珠单抗氨丹宁和帕妥珠单抗在日本HER2阳性转移性乳腺癌患者中的安全性和药代动力学
6. Patient‐reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2–positive breast cancer [O] . PierFranco Conte, Andreas Schneeweiss, Sibylle Loibl, -1

机译：凯瑟琳患者报告的结局：曲妥珠单抗氨丹宁与曲妥珠单抗辅助治疗在人类表皮生长因子受体2阳性乳腺癌新辅助治疗后残留浸润性疾病患者中进行的3期研究
7. 96O Adjuvant trastuzumab emtansine (T-DM1) vs trastuzumab (T) in patients (pts) with residual invasive disease after neoadjuvant therapy for HER2+ breast cancer: Subgroup analysis from KATHERINE [O] . S. Loibl, C-S. Huang, M.S. Mano, 2020

机译：96O佐剂曲妥珠单抗（T-DM1）Emtansine（T-DM1）与HER2 +乳腺癌新辅助治疗后患者（PTS）中的患者（PTS）中的患者（PTS）：来自凯瑟琳的亚组分析

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

客服微信
服务号